statistiche ricercatore

statistiche per ROSSO, Chiara

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7470
AS - Asia 6693
EU - Europa 5562
SA - Sud America 283
OC - Oceania 133
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 13
Totale 20269
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6919
CN - Cina 4662
IT - Italia 1273
DE - Germania 977
SE - Svezia 625
FR - Francia 515
JP - Giappone 400
KR - Corea 374
CA - Canada 370
GB - Regno Unito 346
UA - Ucraina 299
VN - Vietnam 256
TW - Taiwan 232
AT - Austria 211
PL - Polonia 204
TR - Turchia 189
FI - Finlandia 186
RU - Federazione Russa 165
ES - Italia 159
BR - Brasile 157
MX - Messico 155
IN - India 140
AU - Australia 123
GR - Grecia 106
NL - Olanda 102
HK - Hong Kong 96
ID - Indonesia 77
DK - Danimarca 75
RO - Romania 73
EG - Egitto 69
BE - Belgio 49
IR - Iran 45
PT - Portogallo 45
PE - Perù 37
CH - Svizzera 34
SG - Singapore 33
CZ - Repubblica Ceca 28
IL - Israele 28
CO - Colombia 27
TH - Thailandia 27
CL - Cile 26
PK - Pakistan 25
AR - Argentina 20
NO - Norvegia 19
PH - Filippine 19
MY - Malesia 17
SA - Arabia Saudita 17
HU - Ungheria 15
IQ - Iraq 15
EC - Ecuador 14
EU - Europa 12
RS - Serbia 10
IE - Irlanda 9
BY - Bielorussia 8
HR - Croazia 8
NZ - Nuova Zelanda 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
CU - Cuba 6
CV - Capo Verde 6
LB - Libano 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
LT - Lituania 5
PA - Panama 5
PR - Porto Rico 5
PS - Palestinian Territory 5
BG - Bulgaria 4
JO - Giordania 4
MA - Marocco 4
MO - Macao, regione amministrativa speciale della Cina 4
MZ - Mozambico 4
SK - Slovacchia (Repubblica Slovacca) 4
ET - Etiopia 3
SI - Slovenia 3
BF - Burkina Faso 2
CM - Camerun 2
CR - Costa Rica 2
EE - Estonia 2
GD - Grenada 2
GT - Guatemala 2
KE - Kenya 2
SD - Sudan 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
CD - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
GE - Georgia 1
GH - Ghana 1
GU - Guam 1
HN - Honduras 1
IS - Islanda 1
KH - Cambogia 1
LS - Lesotho 1
LV - Lettonia 1
Totale 20260
Salva come PNG Salva come JPEG
Città #
Beijing 1093
Ann Arbor 969
Fairfield 746
Redwood City 468
Houston 466
Shanghai 417
Woodbridge 383
Dearborn 348
Guangzhou 314
Torino 312
Wilmington 311
Villeurbanne 251
Jacksonville 248
Ashburn 232
Ottawa 230
Seattle 230
Pisa 201
Cambridge 200
Vienna 184
Nanjing 183
Hangzhou 176
Dong Ket 172
Wuhan 165
Taipei 161
Jinan 140
Chengdu 134
Warsaw 117
Seoul 116
Fremont 112
Zhengzhou 106
Tokyo 97
Hefei 81
Central District 69
Changsha 69
Shenyang 68
Changchun 67
San Diego 66
Hebei 61
Nanning 61
Chongqing 57
Toronto 57
Rome 55
Kunming 51
Tianjin 51
Fuzhou 50
Xian 48
Nanchang 43
Istanbul 37
Duncan 36
Suzhou 35
San Mateo 33
Munich 32
Harbin 30
New York 30
Phoenix 30
Athens 29
Mexico 29
Norwalk 29
Jakarta 28
London 27
Nürnberg 27
Los Angeles 25
Milan 24
Santiago 23
Lima 22
Pusan 22
Hanoi 21
Redmond 21
Saint Petersburg 21
Seongnam 21
Sydney 20
São Paulo 20
Baotou 19
Lanzhou 18
Madrid 18
Rennes 18
Singapore 18
Düsseldorf 17
Rochester 17
Guiyang 16
Paris 16
Pittsburgh 16
Polska 16
Stanford 16
Hanover 15
Copenhagen 14
Gent 14
Monterrey 14
Moscow 14
Tong 14
Wokingham 14
Ankara 13
Barcelona 13
Falls Church 13
Liverpool 13
Silver Spring 13
Stuttgart 13
Amsterdam 12
Heidelberg 12
Bogotá 11
Totale 11325
Salva come PNG Salva come JPEG
Nome #
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 5161
Serum zonulin in patients with inflammatory bowel disease: a pilot study 962
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 596
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 594
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 481
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 442
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 439
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 411
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 408
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 375
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 345
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 280
Endocrine manifestations of chronic HCV infection 209
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 200
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 198
Fecal calprotectin: beyond intestinal organic diseases 187
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 177
Physiopathology of intestinal barrier and the role of zonulin 157
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 157
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 150
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 149
How to diagnose NAFLD in 2016 139
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 139
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 136
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 133
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 127
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 127
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 126
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 123
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 120
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 115
Non-alcoholic fatty liver disease and extra-hepatic cancers 113
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 110
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 108
Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test 108
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 108
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 105
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 105
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 102
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 102
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 93
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 90
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 90
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 87
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 87
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 85
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C 83
Liver fibrosis: the 2017 state of art 83
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 83
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 83
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 82
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 82
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 80
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 80
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 79
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 79
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 79
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 78
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 78
Basic and clinical aspects of resistin 78
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 77
Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD 76
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 75
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 75
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 74
Metabolic handling of an oral fat load in NAFLD patients. 73
Serum free fatty acid composition is associated with different degrees of fibrosis. 73
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 73
Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy 69
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 69
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 68
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 68
PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C 68
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease? 68
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease 66
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 64
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 63
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 63
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 62
Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients 62
Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience 62
Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients 62
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 62
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 61
Hepatitis B-core related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D 61
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION 61
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 60
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 60
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 60
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 59
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 58
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic NAFLD patients: correlation with liver damage. 57
Peripheral insulin resistance rather than hepatic is a primary defect in non obese, non diabetic, non dyslipidemic nafld patients: correlation with liver damage. 57
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 57
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined cytokeratin-18 apoptotic fragment and elastometry 56
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 56
Integrative hepatic transcriptome analysis identifies biomarkers of non-alcoholic steatohepatitis activity and fibrosis progression 56
IL28B rs12979860 CC Genotype, Metabolic Profile and SVR in Patients with Genotype 1 Chronic Hepatitis C. 55
Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in NASH. 55
Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or agonist II 55
Totale 18539
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21166
article - articoli 0
book - libri 0
conference - conferenze 5508
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/2017416 0000 00 00 00272144
2017/20182736 152282236166 223147 142212 618263176119
2018/20192452 130107116116 192159 143300 180305465239
2019/20204101 203233211433 322521 400331 416444294293
2020/20215413 342439365380 545442 456355 524505457603
2021/20225290 312353406522 494420 599556 6304715270
Totale 21166
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie-Privacy
Logo CINECA  Copyright © 2022